Last reviewed · How we verify
daraprim
At a glance
| Generic name | daraprim |
|---|---|
| Sponsor | Zentrum für Integrative Psychiatrie |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma (EARLY_PHASE1)
- Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (PHASE1, PHASE2)
- Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) (PHASE1)
- LRAs United as a Novel Anti-HIV Strategy. (PHASE1, PHASE2)
- SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) (PHASE1, PHASE2)
- Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy (PHASE3)
- Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR (PHASE1)
- Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- daraprim CI brief — competitive landscape report
- daraprim updates RSS · CI watch RSS
- Zentrum für Integrative Psychiatrie portfolio CI